Cargando…

Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes

Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains. We compared the risk of prematurity, low birth weight (LBW), major congenital malfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bérard, Anick, Strom, Shannon, Zhao, Jin-Ping, Kori, Shashi, Albrecht, Detlef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481540/ https://www.ncbi.nlm.nih.gov/pubmed/34588467 http://dx.doi.org/10.1038/s41598-021-97092-y

Ejemplares similares

Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence
por: Bérard, Anick, et al.
Publicado: (2021)

The Quebec Pregnancy Cohort – Prevalence of Medication Use during Gestation and Pregnancy Outcomes
por: Bérard, Anick, et al.
Publicado: (2014)

Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort
por: Bérard, Anick, et al.
Publicado: (2017)

EHMTI-0125. Studying the permeability of the blood-brain barrier during migraine attacks using [11C]-dihydroergotamine
por: Schankin, C, et al.
Publicado: (2014)

Evaluation of a Monthly Coverage Maximum (Drug-Specific Quantity Limit) on the 5-HT1 Agonists (Triptans) and Dihydroergotamine Nasal Spray
por: Hoffman, Lauren, et al.
Publicado: (2003)

Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors
por: Kori, S, et al.
Publicado: (2013)

Adding acute treatments for patients on triptans: Results of the American Migraine Prevalence & Prevention (AMPP) study
por: Lipton, RB, et al.
Publicado: (2013)

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
por: Albrecht, Detlef, et al.
Publicado: (2020)

Stroke, Migraine and Triptans: From Bedside to Bench
por: Raschi, Emanuel, et al.
Publicado: (2016)

Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort
por: Lemelin, Maxim, et al.
Publicado: (2021)

Consistency vs. switching triptan treatment and headache-related disability: Results of the American migraine prevalence & prevention study
por: Buse, DC, et al.
Publicado: (2013)

Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations
por: Shafqat, Rafia, et al.
Publicado: (2020)

Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
por: Cooper, Wade, et al.
Publicado: (2022)

Prevalence and duration of prescribed opioid use during pregnancy: a cohort study from the Quebec Pregnancy Cohort
por: Zhao, Jin-Ping, et al.
Publicado: (2021)

Headaches related to triptans therapy in patients of migrainous vertigo
por: Prakash, Sanjay, et al.
Publicado: (2008)

Efficacy of frovatriptan as compared to other triptans in migraine with aura
por: Evers, Stefan, et al.
Publicado: (2015)

Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat
por: Mullins, C. Daniel
Publicado: (2005)

Validation of the nausea and vomiting of pregnancy specific health related quality of life questionnaire
por: Lacasse, Anaïs, et al.
Publicado: (2008)

Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms
por: Kogelman, Lisette J. A., et al.
Publicado: (2023)

Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache
por: Robbins, Nathaniel M., et al.
Publicado: (2016)

Triptans Use for Migraine Headache among Nonelderly Adults with Cardiovascular Risk
por: Alwhaibi, Monira, et al.
Publicado: (2016)

Triptans in prevention of menstrual migraine: a systematic review with meta-analysis
por: Hu, Yong, et al.
Publicado: (2013)

Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010)

Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine
por: Gentile, Giovanna, et al.
Publicado: (2010)

Network meta-analysis of migraine disorder treatment by NSAIDs and triptans
por: Xu, Haiyang, et al.
Publicado: (2016)

Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case–control study
por: Dandjinou, Maëlle, et al.
Publicado: (2019)

Ictal lack of binding to brain parenchyma suggests integrity of the blood–brain barrier for (11) C-dihydroergotamine during glyceryl trinitrate-induced migraine
por: Schankin, Christoph J., et al.
Publicado: (2016)

Up to date on the use of triptans for child and adolescent migraine: state of the art
por: Calderoni, Dario, et al.
Publicado: (2001)

Acute treatment patterns in patients with migraine newly initiating a triptan
por: Lipton, Richard B, et al.
Publicado: (2020)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

The French Pregnancy Cohort: Medication use during pregnancy in the French population
por: Bérard, Anick, et al.
Publicado: (2019)

Costs and Utilization of Triptan Users Who Receive Drug Prophylaxis for Migraine Versus Triptan Users Who Do Not Receive Drug Prophylaxis
por: Etemad, Lida R., et al.
Publicado: (2005)

Association of Maternal Use of Triptans During Pregnancy With Risk of Attention-Deficit/Hyperactivity Disorder in Offspring
por: Harris, Gerd Marie, et al.
Publicado: (2022)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Dihydroergotamine (DHE) – Then and Now: A Narrative Review
por: Silberstein, Stephen D., et al.
Publicado: (2019)

Polymorphisms of the Proinflammatory Cytokine Genes Modulate the Response to NSAIDs but Not to Triptans in Migraine Attacks
por: Rubino, Elisa, et al.
Publicado: (2022)

Is in-utero exposure to cannabis associated with the risk of attention deficit with or without hyperactivity disorder? A cohort study within the Quebec Pregnancy Cohort
por: Tchuente, Vanina, et al.
Publicado: (2022)

Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study
por: Yusuf, Akeem, et al.
Publicado: (2018)

Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy
por: Bérard, Anick, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kpsgdsf2fh6492kiupi19ltisg